Ignacio Garrido-Laguna, MD
Medical Oncology · Salt Lake City, UTNPI 1467608554
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by AbbVie at 27.9% of the total. Reporting peaked in 2024 at $10,329 and has fallen 61.0% since, to $4,025 in 2025.
Across 40 payments — averaging $867.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Eisai Inc.$7K
- Eli Lilly$5K
- Array Biopharma Inc$4K
- Incyte Corporation$3K
- Jazz Pharmaceuticals Inc.$3K
- plus $4K from 3 others
Across 1,004 payments — averaging $8788.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.9M
- Novartis$1.4M
- Pfizer$1.1M
- Array Biopharma Inc$579K
- GSK$562K
- AstraZeneca$403K
- plus $2.9M from 16 others
What the payments were for
- Consulting fees$19,11055%
- Speaking & faculty fees$9,28627%
- Travel & lodging$5,52216%
- Food & beverage$7972%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 7 | $9,687 |
| Eisai Inc. | 10 | $6,776 |
| Eli Lilly | 10 | $4,732 |
| Array Biopharma Inc | 1 | $4,200 |
| Incyte Corporation | 1 | $2,639 |
| Jazz Pharmaceuticals Inc. | 1 | $2,560 |
| F. Hoffmann-la Roche AG | 4 | $2,447 |
| Pfizer | 5 | $1,496 |
| Redhill Biopharma Inc. | 1 | $178 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$6,540
- MEKTOVI$4,200
- ZEPZELCA$2,560
- Non-Covered Product$2,447
How this compares
$34,715 in reported general payments places this provider in the 80th percentile of 43 medical oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Salt Lake City
- Bradley HunterSalt Lake City$263K
- Robert HavardSalt Lake City$57K
- Wallace AkerleySalt Lake City$38K
- Mei WeiSalt Lake City$34K
- Xylina GreggSalt Lake City$31K
- Paul ShamiSalt Lake City$28K
- Nitin ChandramouliSalt Lake City$19K
- Kenneth GrossmannSalt Lake City$15K
- Manish KohliSalt Lake City$13K
- Peter HaleSalt Lake City$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.